Biosimilars market value could triple by 2020, says report

The market value for biosimilars around the world could reach $20 billion by the end this year and that figure could nearly triple by 2020, according to a report.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

The plausibility battleground at the EPO

9 November 2020 Plausibility in the context of the inventive step and sufficiency requirements can be a contentious issue before the European Patent Office. Markus Grammel of Grünecker reports.

Biotechnology

Association calls for more biosimilar cancer therapies in Europe

11 October 2018 Cancer biosimilars are slow to enter European drugs markets even after the branded products have gone off-patent, according to the Association of European Cancer Leagues.

Americas

US FDA approves first biosimilar, keeps quiet on naming standards

9 March 2015 The US Food and Drug Administration approved Sandoz’s cancer product Zarxio on Friday—the first biosimilar to be rubber stamped in the US.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Biosimilars market value could triple by 2020, says report

More on this story

Editor's picks

Editor's picks

More features